The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2016

Filed:

May. 22, 2009
Applicants:

Kaja Kiiver, Tartu, EE;

Rein Sikut, Tartu, EE;

Urve Toots, Tartu, EE;

Tarmo Mölder, Tartu, EE;

Andres Männik, Tartu, EE;

Mart Ustav, Tartu, EE;

Katrin Kaldma, Tartu, EE;

Inventors:

Kaja Kiiver, Tartu, EE;

Rein Sikut, Tartu, EE;

Urve Toots, Tartu, EE;

Tarmo Mölder, Tartu, EE;

Andres Männik, Tartu, EE;

Mart Ustav, Tartu, EE;

Katrin Kaldma, Tartu, EE;

Assignee:

FIT Biotech OY, Tampere, FI;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 48/00 (2006.01); A61K 39/39 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 9/12 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 9/127 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55516 (2013.01); C07K 2319/09 (2013.01); C12N 2710/20022 (2013.01); C12N 2770/36122 (2013.01);
Abstract

The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.


Find Patent Forward Citations

Loading…